Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model

Acta Ophthalmologica

Volumn 90, Issue 6, 2012, Pages 564-570

  Akkoyun, Imren ^a   Karabay, Gulten ^a   Haberal, Nihan ^a   Dagdeviren, Attila ^a   Yilmaz, Gursel ^a   Oto, Sibel ^a   Erkanli, Leyla ^a   Akova, Yonca A ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

apoptosis; electron microscopy; intravitreal bevacizumab; mitochondria; retinal endothelial cells; retinopathy of prematurity mouse model

Indexed keywords

BEVACIZUMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL COUNT; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HISTOLOGY; HYPEROXIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RETINA CELL; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; TERATOLOGY; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL COUNT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; IN SITU NICK-END LABELING; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON; MITOCHONDRIA; PHOTORECEPTOR CELLS, VERTEBRATE; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865694831     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.01963.x     Document Type: Article

References (40)

1. Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, &, Humayun MS, (2007): The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci 48: 5708-5715. (Pubitemid 351260875)
2. Arevalo JF, Sanchez JG, Fromow-Guerra J, Wu L, Berrocal MH, Farah ME, Cardillo J, &, Rodriguez FJ, (2009): Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 247: 735-743.
3. Avci B, Avci R, Inan UU, &, Kaderli B, (2009): Comparative evaluation of apoptotic activity in thotoreceptor cells after intravitreal injection of bevacizumab and pegaptamib sodium in rabbits. Invest Ophthalmol Vis Sci 50: 3438-3446.
4. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, &, Marler RJ, (2006): Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142: 162-164. (Pubitemid 43946808)
5. Benitez-Bribiesca L, Gomez-Camarillo M, Castellanos-Juarez E, Mravko E, &, Sanchez-Suarez P, (2000): Morphologic, biochemical and molecular mitochondrial changes during reperfusion phase following brief renal ischemia. Ann N Y Acad Sci 926: 165-179. (Pubitemid 32050154)
6. Benninghof A, &, Dreckhahn D, (2008): Anatomie 1. München: Urban & Fischer, 61-81.
7. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, &, Cursiefen C, (2007): Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48: 2545-2552. (Pubitemid 351261204)
8. Bonnin P, Pournaras JAC, Lazrak Z, Cohen YS, &, Legargasson JF, (2009): Ultrasound assesment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age-related macular degeneration. Acta Ophthalmol, doi:10.1111/j.1735-3768.2009.01526.x
9. Dayhaw-Barker P, (2002): Retinal pigment epithelium melanin and ocular toxicity. Int J Toxicol 21: 451-454. (Pubitemid 36090834)
10. Detmer SA, &, Chan DC, (2007): Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8: 870-879. (Pubitemid 47622562)
11. Dorfman AL, Dembinska O, Chemtob S, &, Lachapelle P, (2006): Structural and functional consequences of trolox C treatment in the rat model of postnatal hyperoxia. Invest Ophthalmol Vis Sci 47: 1101-1108. (Pubitemid 46768345)
12. Ferrara N, Hillan KJ, Gerber HP, &, Novotny W, (2004): Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400. (Pubitemid 38618122)
13. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, &, Guyer DR, (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816. (Pubitemid 40051904)
14. Habot-Wilner Z, Barequet SI, Ivanir Y, Moisseiev J, &, Rosner M, (2009): The inhibitory effect of different concentrations of topical bevacizumab on corneal neovacularization. Acta Ophthalmol, doi:10.1111/j.1755-3768.2009. 01571.x
15. Harmey JH, &, Bouchier-Hayes D, (2002): Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 24: 280-283. (Pubitemid 34248694)
16. Heiduschka P, Fietz H, Hofmeister S, et al., (2007): Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 2814-2823. (Pubitemid 351261238)
17. Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, &, Schraermeyer U, (2008): Bevacizumab (avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 28: 46-55.
18. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, &, Temel SG, (2007): Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773-1781. (Pubitemid 351261365)
19. Kim JH, Kim C, Kim HJ, Lee JB, Yu SK, Park HK, &, Kim WY, (2008): Absence of intravitreal bevacizumab induced neuronal toxicity in the retina. Neurotoxicology 29: 1131-1135.
20. Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, &, Schmidt-Erfurth U, (2009): Effect of intravitreal bevacizumab (Avastin(R)) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol [Epub ahead of print].
21. Liu W, Ahmad SA, Reinmuth N, Shaheen RM, Jung YD, Fan F, &, Ellis LM, (2000): Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5: 323-328.
22. Manzano RP, Peyman GA, Khan P, &, Kivilcim M, (2006): Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26: 257-261. (Pubitemid 44318176)
23. Mintz-Hittner HA, &, Kuffel RR Jr, (2008): Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28: 831-838.
24. Mitchell P, Smith W, Wang JJ, &, Attebo K, (1998): Prevalence of diabetic retinopathy in an older community. The Blue Mountains Eye Study. Ophthalmology 105: 406-411. (Pubitemid 28125091)
25. Mordenti J, Cuthbertson RA, Ferrara N, et al., (1999): Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27: 536-544. (Pubitemid 29446822)
26. Natoli R, Provis J, Valter K, &, Stone J, (2008): Expression and role of the early-response gene Oxr1 in the hyperoxia-challenged mouse retina. Invest Ophthalmol Vis Sci 49: 4561-4567.
27. Oyster CW, (1999): The human eye: structure anc function. Sunderland, MA: Sinauer Ass., Raven Press, 491-544, http://prometheus.med.utah.edu/marclab/ protocols.html
28. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, &, Schraermeyer U, (2007): Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995-1002.
29. Pierce EA, Foley ED, &, Smith LE, (1996): Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 114: 1219-1228. (Pubitemid 26338853)
30. Remtulla S, &, Hallett PE, (1985): A schematic eye for the mouse, and comparisons with the rat. Vision Res 25: 21-31, http://prometheus.med.utah.edu/ marclab/protocols.html, Mouse Schematic Eye Remtulla & Hallet 1985 Vision Res 25: 21-31. (Pubitemid 15165475)
31. Rich RM, Rosenfeld PJ, Puliafito CA, et al., (2006): Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495-511. (Pubitemid 44620390)
32. Robins, &, Cotran, (2005): Pathologic basis of disease, 7th edn. Elsevier Saunders, Philadelphia, PA.
33. Schmucker C, &, Schaeffel F, (2004): A paraxial schematic eye model for the growing C57Bl/6 mouse. Vision Res 44: 1857-1867. (Pubitemid 38624338)
34. Shahar J, Avery RL, Heilweil G, et al., (2006): Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26: 262-269. (Pubitemid 44318177)
35. Sharma KR, &, Chalam KV, (2009): In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta Ophthalmol 87: 618-622.
36. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, &, D'Amore PA, (1994): Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111. (Pubitemid 24046832)
37. Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, &, Szurman P, (2006): Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 90: 1316-1321. (Pubitemid 44621499)
38. Stolk RP, Vingerling JR, de Jong PT, Dielemans I, Hofman A, Lamberts SW, Pols HA, &, Grobbee DE, (1995): Retinopathy, glucose, and insulin in an elderly population. The Rotterdam Study. Diabetes 44: 11-15.
39. Zhang Q, Zhang J, Guan Y, Zhang S, Zhu C, Xu GT, &, Wang L, (2009): Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol 247: 919-927.
40. Zhou X, Shen M, Xie J, Wang J, Jiang L, Pan M, Qu J, &, Lu F, (2008): The development of the refractive status and ocular growth in C57BL/6 mice. Invest Ophthalmol Vis Sci 49: 5208-5214.